In addition, a DNA plasmid named H19-DTA (also known as BC-819), which targets the expression of a fragment of the diphtheria toxin (DT-A) under the control of the H19 promoter, provides a feasible novel therapeutic option for H19-targeted cancer therapy [130, 131]. This evidence concerns the gene H19 and cancer.